Ipsen’s partner, Lexicon Pharmaceuticals, announces positive results from TELESTAR phase 3 study showing that telotristat etiprate is effective in the treatment of carcinoid syndrome caused by neuroendocrine tumors not adequately controlled by somatostatin analogs
This article or press release has no online content. Please download the associated documents for more information.
You are now leaving the Ipsen Group section. If you would like to visit an affiliate section, please click Continue. The information provided on this section may not necessarily be applicable to the Ipsen Group.